Upcoming Events
  1. ALTG open MAC and SAC meetings

    November 20
  2. Virtual 2020 World Conference on Lung Cancer Singapore

    January 28, 2021 @ 8:00 am - January 31, 2021 @ 5:00 pm

Thoracic oncology highlights from ASCO2020 webinar- recording and evaluation survey

Please fill in the evaluation survey if you have not already done so by clicking on the survey icon at the base of your webinar console.

Please access the recording and evaluation survey here

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.

ALTG 13/002 Health related quality of life in Malignant Mesothelioma – H Dhillon

This project will explore longitudinal HQOL, anxiety and depression and supportive care needs in Mesothelioma. The relationships between HQOL and other prognostic factors such as inflammatory markers, malnutrition and functional status will also be explored.

Participation will involve collecting routine medical information and completing a series of questionnaires at baseline and at regular follow up intervals for 2 years or until death. There will also be the option to participate in additional nutritional and functional assessments.

The project received ethical approval under the multi-site approval process in August 2013. Site-specific ethics approval has been received for 15 sites across NSW, QLD, VIC and SA. To date, 90 participants have been recruited with 33 currently active on the study. Thirty participants have deceased, 17 have withdrawn (primarily due to disease progression) and 10 participants have completed their 2-year involvement in the study. Recruitment rates at each site are listed below.

SiteRecruitment
Concord Hospital4
ADRI26
Northern Cancer Institute6
Prince of Wales Hospital3
Royal Prince Alfred Hospital
Westmead Hospital4
The Prince Charles Hospital16
Strathfield Private Hospital
Central West Cancer Service, Orange Health Service6
Macarthur Cancer Therapy Centre, Campbelltown Hospital2
Liverpool Hospital6
Alan Coates Cancer Centre, Dubbo Base Hospital
Flinders Medical Centre1
Chris O'Brien Lifehouse15
Austin Health1

We are recruiting patients at any stage of their disease and their cancer journey. Once a participant has been consented our research team undertakes all ongoing management of their involvement in the study. The project received ALTG endorsement in March 2013 and is supported by a translational research grant from Cancer Institute NSW.

Study contacts

Investigators: A/Prof Janette Vardy, Dr Haryana Dhillon, Dr Steven Kao, Dr Melanie Price, Dr Cindy Tan and Ms Jocelyn McLean.

Study Coordinator: Mr Jason Fowler jason.fowler@sydney.edu.au